EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety and Effectiveness of Vibegron in Japanese Patients With Overactive Bladder: A Japanese Postmarketing Survey

Shoko Yoshimura iD, Hiromitsu Yagi, Kazunori Abe, Masakazu Yamasaki

LUTS: Lower Urinary Tract Symptoms · 2024

DOI: 10.1111/luts.12535 ↗

Kurz gefasst

Fachartikel in der Zeitschrift LUTS: Lower Urinary Tract Symptoms, 2024. Verfasst von Shoko Yoshimura und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacovigilance Department, Kyorin Pharmaceutical Co. Ltd., Tokyo, Japan. Hauptthemen laut MEDLINE: Adrenergic beta-3 Receptor Agonists, Product Surveillance, Postmarketing, Pyrrolidines, Urinary Bladder, Overactive. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kissei Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Kyorin Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the safety and effectiveness of vibegron, a highly selective β 3 ‐adrenoceptor agonist, in Japanese patients with overactive bladder (OAB) in a real‐world clinical setting.

Methods

This prospective survey was conducted from August 2019 to July 2023 using a central registration method. Patients newly treated with vibegron for OAB were followed for 12 weeks, and those who continued treatment were observed for up to 52 weeks. Adverse drug reactions (ADRs) and the overall improvement level were assessed, and overactive bladder symptom score (OABSS) and International Prostate Symptom Score‐Quality of Life (IPSS QOL) score were collected.

Results

Of the 1848 patients in the safety analysis set, 154 ADRs were reported in 141 patients (7.63%). Common ADRs were increased residual urine volume (1.30%), constipation (1.14%), dysuria and urinary retention (0.97% each), cystitis (0.65%), and dry mouth (0.32%). The incidence of urinary retention‐related adverse events (AEs) was higher in male patients, patients ≥ 65 years old, and patients with benign prostatic hyperplasia. The effectiveness rate was 88.8% among the 1561 patients in the effectiveness analysis set. Significant improvement in both OABSS and IPSS QOL scores was observed at all observation periods. The rate of achieving the minimal clinically important change in OABSS total score at the final evaluation was 75.35%. OABSS scores were also significantly reduced in all subgroup analyses.

Conclusions

This survey found no major concerns regarding the safety and effectiveness of vibegron in Japanese OAB patients, except for urinary retention‐related AEs. Vibegron is considered to represent a useful drug for treating OAB symptoms in a real‐world clinical setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenergic beta-3 Receptor AgonistsProduct Surveillance, PostmarketingPyrrolidinesUrinary Bladder, OveractivePyrimidinonesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedEast Asian PeopleJapanProspective StudiesQuality of LifeTreatment Outcome

Stichwörter der Autor:innen

overactive bladderpostmarketing surveyvibegronβ3‐adrenoceptor agonist

Substanzen

Adrenergic beta-3 Receptor AgonistsN-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carbo…PyrrolidinesPyrimidinones

Autor:innen und Institutionen

  • Pharmacovigilance Department, Kyorin Pharmaceutical Co. Ltd., Tokyo, Japan.
  • Pharmacovigilance & Post-Marketing Surveillance, Kissei Pharmaceutical Co. Ltd., Tokyo, Japan.

ORCID-Profile: Shoko Yoshimura

Förderung

  • Kissei Pharmaceutical Co. Ltd.
  • Kyorin Pharmaceutical Co. Ltd.
  • Kyorin Pharmaceutical

Zitieren

APA

Yoshimura, S., Yagi, H., Abe, K., & Yamasaki, M. (2024). Safety and Effectiveness of Vibegron in Japanese Patients With Overactive Bladder: A Japanese Postmarketing Survey. LUTS: Lower Urinary Tract Symptoms. https://doi.org/10.1111/luts.12535

Vancouver

Yoshimura S, Yagi H, Abe K, Yamasaki M. Safety and Effectiveness of Vibegron in Japanese Patients With Overactive Bladder: A Japanese Postmarketing Survey. LUTS: Lower Urinary Tract Symptoms. 2024. doi:10.1111/luts.12535

BibTeX
@article{Yoshimura2024,
  author = {Yoshimura, Shoko and Yagi, Hiromitsu and Abe, Kazunori and Yamasaki, Masakazu},
  title = {Safety and Effectiveness of Vibegron in Japanese Patients With Overactive Bladder: A Japanese Postmarketing Survey},
  journal = {LUTS: Lower Urinary Tract Symptoms},
  year = {2024},
  doi = {10.1111/luts.12535}
}
Kostenlos starten →